Previous structure-activity relationship studies in the search for a potent, noncompetitive alpha-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic acid (AMPA) receptor antagonist led to 2,3-dimethyl-6-phenyl-12H-[1,3]dioxolo[4,5-h]imidazo[1,2-c][2,3]benzodiazepine (ZK 187638). However, the first synthesis had some drawbacks regarding reagents, processes, and overall yield, which furthermore decreased when the synthesis was scaled up. Therefore, we now report a new synthetic route for this compound which requires fewer steps and is suited for large-scale production. This compound significantly relieved the symptoms of neuromuscular deficit in mnd mice, a model of neuronal ceroid lipofuscinosis with motor neuron dysfunction. After oral administration, the concentrations of the compound in the brain and spinal cord were about threefold higher than those in the plasma. In summary, this novel AMPA antagonist is accessible through an optimized synthetic route, has good neurobehavioral activity, oral bioavailability, and favorable brain penetration. This opens new possibilities for the treatment of devastating neurological diseases that are mediated by the AMPA receptor.
Optimized synthesis of AMPA receptor antagonist ZK 187638 and neurobehavioral activity in a mouse mode of neuronal ceroid lipofuscinosis / B. Elger, M. Schneider, E. Winter, L. Carvelli, M. Bonomi, C. Fracasso, G. Guiso, M. Colovic, S. Caccia, T. Mennini. - In: CHEMMEDCHEM. - ISSN 1860-7179. - 1:10(2006 Oct), pp. 1142-1148. [10.1002/cmdc.200600144]
Optimized synthesis of AMPA receptor antagonist ZK 187638 and neurobehavioral activity in a mouse mode of neuronal ceroid lipofuscinosis
M. Bonomi;
2006
Abstract
Previous structure-activity relationship studies in the search for a potent, noncompetitive alpha-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic acid (AMPA) receptor antagonist led to 2,3-dimethyl-6-phenyl-12H-[1,3]dioxolo[4,5-h]imidazo[1,2-c][2,3]benzodiazepine (ZK 187638). However, the first synthesis had some drawbacks regarding reagents, processes, and overall yield, which furthermore decreased when the synthesis was scaled up. Therefore, we now report a new synthetic route for this compound which requires fewer steps and is suited for large-scale production. This compound significantly relieved the symptoms of neuromuscular deficit in mnd mice, a model of neuronal ceroid lipofuscinosis with motor neuron dysfunction. After oral administration, the concentrations of the compound in the brain and spinal cord were about threefold higher than those in the plasma. In summary, this novel AMPA antagonist is accessible through an optimized synthetic route, has good neurobehavioral activity, oral bioavailability, and favorable brain penetration. This opens new possibilities for the treatment of devastating neurological diseases that are mediated by the AMPA receptor.File | Dimensione | Formato | |
---|---|---|---|
Elger_SAG02_2006.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
314.43 kB
Formato
Adobe PDF
|
314.43 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Elger_et_al-2006-ChemMedChem.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
127.75 kB
Formato
Adobe PDF
|
127.75 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.